Eric Venker - 06 Oct 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
President & Immunovant CEO
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Issuer symbol
ROIV
Transactions as of
06 Oct 2025
Net transactions value
-$4,825,781
Form type
4
Filing time
08 Oct 2025, 21:00:39 UTC
Previous filing
23 Sep 2025
Next filing
14 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Venker Eric President & Immunovant CEO C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker 08 Oct 2025 0001801917

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Options Exercise $2,018,577 +127,355 +8.5% $15.85 1,632,314 06 Oct 2025 Direct
transaction ROIV Common Shares Options Exercise $185,505 +24,900 +1.5% $7.45 1,657,214 06 Oct 2025 Direct
transaction ROIV Common Shares Options Exercise $73,693 +19,141 +1.2% $3.85 1,676,355 06 Oct 2025 Direct
transaction ROIV Common Shares Sale $2,800,611 -171,396 -10% $16.34 1,504,959 06 Oct 2025 Direct F1
transaction ROIV Common Shares Options Exercise $1,064,660 +67,171 +4.5% $15.85 1,572,130 07 Oct 2025 Direct
transaction ROIV Common Shares Options Exercise $798,126 +107,131 +6.8% $7.45 1,679,261 07 Oct 2025 Direct
transaction ROIV Common Shares Options Exercise $696,307 +180,859 +11% $3.85 1,860,120 07 Oct 2025 Direct
transaction ROIV Common Shares Sale $5,735,850 -355,161 -19% $16.15 1,504,959 07 Oct 2025 Direct F1
transaction ROIV Common Shares Options Exercise $163,366 +10,307 +0.68% $15.85 1,515,266 08 Oct 2025 Direct
transaction ROIV Common Shares Options Exercise $955,798 +128,295 +8.5% $7.45 1,643,561 08 Oct 2025 Direct
transaction ROIV Common Shares Sale $2,245,352 -138,602 -8.4% $16.20 1,504,959 08 Oct 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -127,355 -11% $0.000000 1,054,528 06 Oct 2025 Common Stock 127,355 $15.85 Direct F2
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -24,900 -9.6% $0.000000 235,426 06 Oct 2025 Common Stock 24,900 $7.45 Direct F3
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -19,141 -0.3% $0.000000 6,457,382 06 Oct 2025 Common Stock 19,141 $3.85 Direct F4
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -67,171 -6.4% $0.000000 987,357 07 Oct 2025 Common Stock 67,171 $15.85 Direct F2
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -107,131 -46% $0.000000 128,295 07 Oct 2025 Common Stock 107,131 $7.45 Direct F3
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -180,859 -2.8% $0.000000 6,276,523 07 Oct 2025 Common Stock 180,859 $3.85 Direct F4
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -10,307 -1% $0.000000 977,050 08 Oct 2025 Common Stock 10,307 $15.85 Direct F2
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -128,295 -100% $0.000000 0 08 Oct 2025 Common Stock 128,295 $7.45 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
F2 Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.
F3 Award of stock options to purchase Common Shares with a vesting commencement date of October 16, 2017. These options are fully vested.
F4 Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).